*💡 What’s This About?*
A new study published in BMC Cancer examined an innovative combination of two drugs – Pyrotinib and *Etoposide* in metronomic dosing (low continuous dosing) in patients who had undergone multiple previous treatments for HER2-positive metastatic breast cancer 🏥
*⚕ How Does It Work?*
Pyrotinib is a drug targeting the HER2 protein, and *Etoposide* is a chemotherapy drug given in low continuous doses. Their combination is designed to create a synergistic effect against the disease 💊
*📊 What Did the Study Find?*
The results are particularly encouraging! ✨
* 30% of patients responded to treatment
* Median time to disease progression was 9 months
* Median survival duration was 27 months
* Disease control was achieved in 80% of patients
* Side effects were manageable and no severe side effects were observed
*🌟 Why Is This Important?*
This is significant news for patients who have undergone multiple treatments! The drug combination offers a new and promising therapeutic option, especially for patients who have exhausted previous treatment options 🙏
Remember, we’re here for you ❤
**📲 Share this post – it might help someone you know! 🤝**
Yours,
Nir Erez / Trial-In Pharma 👨⚕
Read the full article >> *https://bmccancer.biomedcentral.com/articles/10.1186/s12885-024-13041-8*
